Editor's Note
Truly Misguided Decision-Making
CMS is doubling down on including non-invasive vents in Round 2021. How is the HME industry responding? How can you help?
- By David Kopf
- Dec 01, 2019
Doesn’t it drive you nuts when
someone doubles down on a bad idea? What level
of intractability do you have to achieve to commit
to a position that you know, deep down, is simply
awful to hold? I’ve been asking myself that since
CMS announced in March that it would add non-invasive
ventilators to the list of products covered
by Round 2021 of competitive bidding.
At the time, the level of shock from the industry
was understandably severe — we’re talking about
vulnerable patients that use these devices. People
who use non-invasive vents include patients with
neuromuscular diseases such as ALS, as well as
end-stage COPD and other terminal respiratory
conditions. From my point of view, the decision
seemed downright cruel. I think Tom Ryan, the
president and CEO of the American Association for
Homecare put it well at that time:
“Subjecting these highly specialized, service-intensive
products to a reimbursement methodology
designed to find the lowest-cost providers
will ultimately have the effect of further narrowing
the relatively small number of companies that
supply ventilators and driving some of the most
effective and caring vent providers out of the
Medicare program,” he stated back then. “Access
to these ventilators will become more limited
and many current patients will be separated from
companies and respiratory professionals who have
been with them for years.”
Sharing the industry’s shock, Reps. Morgan
Griffith (R-Va.) and Peter Welch (D-Vt.) circulated
a Congressional sign-on letter in the House in May
that asked HHS Secretary Alex Azar and CMS
Administrator Seema Verma to reverse the decision
to add non-invasive ventilators to Round 2021.
The House letter made clear that Congress
“never specifically directed the Secretary to
competitively bid ventilators, and Medicare has
never attempted to bid any items within its entire
DME category of devices requiring frequent and
substantial servicing.” The letter went on to say,
“CMS has never proposed including ventilators in
the program through rulemaking and we would
encourage you to solicit such input on the record
before doing so.”
In October, Verma responded individually to
the 180 Representatives that signed Reps. Griffith’s
and Welch’s letter, saying that Medicare had
implemented measures to protect access. However,
the response didn’t address other concerns in
the House sign-on letter, such as the idea that
CMS needed to ensure that Medicare payment
for critical services such as home ventilatory care
were adequate, as well as the fact that up until its
vent decision, CMS had never included items that
required frequent and substantial servicing as part
of its bid program.
Rep. Griffith responded to CMS’s “non-response”
in comments he made later that month in a
hearing on Administration healthcare policy by the
Oversight & Investigations Subcommittee of the
House Energy & Commerce Committee.
“I just got your letter yesterday afternoon in
response to that letter, where you said we’re not
going to do it on invasive,” he stated. “But here’s the
problem I have: I have a rural district, as does my
friend Mr. Welch. What happens is that if you go to
this cost-only issue, you’re going to make someone
drive 45 minutes to an hour … if the low-cost
supplier is only located in town. I would ask you
to really take a look at that because, in the rural
districts, our folks are not going to get served.”
At that point, there was really only one response
left: legislation. Rep. Griffith and Rep. Welch were
joined by Reps. John Larson (D-Conn), Darren
Soto (D-Fla.) and Gus Bilirakis (R-Fla.) to launch
The Safeguarding Medicare Access to Respiratory
Therapy (SMART) Act, a House bill that would
delay the inclusion of all types of ventilators in
competitive bidding by five years.
Now it’s time for everyone in the industry
to advocate on behalf of this bill. Contact your
Representative and urge that he or she co-sponsor
this critical legislation. The stakes are too high.
This article originally appeared in the Nov/Dec 2019 issue of HME Business.
About the Author
David Kopf is the Publisher HME Business, DME Pharmacy and Mobility Management magazines. He was Executive Editor of HME Business and DME Pharmacy from 2008 to 2023. Follow him on LinkedIn at linkedin.com/in/dkopf/ and on Twitter at @postacutenews.